News & Views | Published:

Immunology

JAK3 inhibition—is it sufficient?

Nature Chemical Biology volume 12, pages 308310 (2016) | Download Citation

A highly selective JAK3 inhibitor with subnanomolar potency has been used to identify two waves of STAT5 phosphorylation in response to IL-2. This reveals a biphasic role for JAK3 catalytic activity in IL-2-mediated signaling that has therapeutic implications.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Annu. Rev. Immunol. 16, 293–322 (1998).

  2. 2.

    , , & Nat. Chem. Biol. 12, 373–379 (2016).

  3. 3.

    , & Immunity 38, 13–25 (2013).

  4. 4.

    et al. Cell 73, 147–157 (1993).

  5. 5.

    et al. Nature 377, 65–68 (1995).

  6. 6.

    et al. Science 270, 797–800 (1995).

  7. 7.

    et al. Science 302, 875–878 (2003).

  8. 8.

    et al. Chem. Biol. 18, 314–323 (2011).

  9. 9.

    Clin. Immunol. 27, 1–18 (2007).

  10. 10.

    et al. Immunity 42, 826–838 (2015).

Download references

Author information

Affiliations

  1. Warren J. Leonard, Suman Mitra and Jian-Xin Lin are in the Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, US National Institutes of Health, Bethesda, Maryland, USA.

    • Warren J Leonard
    • , Suman Mitra
    •  & Jian-Xin Lin

Authors

  1. Search for Warren J Leonard in:

  2. Search for Suman Mitra in:

  3. Search for Jian-Xin Lin in:

Competing interests

W.J.L. and S.M. are inventors related to a patent application on H9-RETR.

Corresponding author

Correspondence to Warren J Leonard.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nchembio.2066

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing